Empagliflozin near to us: Insights from its use in Asians

09 Jul 2020
In this fourth issue, join us as we discover the unique biology Asians have with respect to diabetes. Take a closer look at trials evaluating whether empagliflozin’s cardiovascular and renal benefits – as analysed in Asians – are consistent with the overall trial population, and how it addresses unmet needs.

Related MIMS Drugs

Editor's Recommendations